Walder Wyss with Allegria on USD 5.1 million funding round
Walder Wyss advised Allegria Therapeutics, a Basel-based biotech company developing therapies for mast cell-mediated diseases, throughout its USD 5.1 million seed extension funding round.
The context
ALK Abelló led the round in question, with support from HighLight Capital, Lichtsteiner Foundation and co-founding investor Forty51 Ventures.
The financing proceeds will support advancement of the company’s lead program toward preclinical and first clinical candidate nomination, as well as the development of discovery-stage programs.
The Walder Wyss team
The Walder Wyss team working on the matter included partner Alexander Gutmans (pictured), managing associate Karina Tschon and associate Oerjan Wickart — all corporate/M&A and venture capital.
